A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers.

Trial Profile

A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2013

At a glance

  • Drugs Gabapentin enacarbil (Primary) ; Moxifloxacin
  • Indications Diabetic neuropathies; Postherpetic neuralgia; Restless legs syndrome
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; XenoPort
  • Most Recent Events

    • 25 Mar 2013 Lead trial centre amended as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
    • 12 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top